Medindia

X

Elbit Imaging Announces InSightec's First Non-Invasive Technology for Treatment of Uterine Fibroids Awarded MHLW Approval in Japan

Thursday, January 14, 2010 Press Release J E 4
Advertisement
TEL AVIV, January 14 Elbit Imaging Ltd.(NASDAQ: EMITF) ("Elbit" "Company") that its subsidiary, InSightec Ltd.,announced today that Japan's Ministry of Health, Labor and Welfare (MHLW) hasapproved the company's ExAblate(R) MR-guided Focused Ultrasound (MRgFUS)system for the treatment of women with uterine fibroids.

ExAblate is currently the only noninvasive treatment for uterine fibroidsapproved for use in Japan.

InSightec Ltd. estimates that approximately 25% of Japanese women willdevelop symptomatic uterine fibroids, primarily during childbearing years.These benign tumors can significantly impair functionality and degradequality of life, resulting in significant work absences.

Using the ExAblate system, the physician uses the Magnetic ResonanceImaging (MRI) to visualize the patient's anatomy and then aims focusedultrasound waves at the targeted tissue to thermally ablate, or destroy it.The MRI allows the physician to monitor and continuously adjust the treatmentin real time. An additional benefit of using InSightec's ExAblate system isthat during the procedure to destroy the targeted tissue, patients requireonly limited conscious sedation as opposed to full sedation.

The ExAblate system received the CE Mark for uterine fibroids in October2002 and US Food and Drug Administration (FDA) approval in 2004. Over 5,500women around the world have chosen to undergo the non-invasive ExAblatetreatment for their symptomatic uterine fibroids over invasive surgery.

GE Healthcare is the approval holder and distributor of ExAblate in Japan.

Dr. Kobi Vortman, President and Chief Executive Officer of InSightec,said: "The approval was based on a growing body of evidence showing thatExAblate is a safe, effective, and durable treatment for this widespread,life-impacting condition. ExAblate is an outpatient procedure and patientsnormally return home the same day and to work within one to two days comparedto lengthy hospitalizations and recovery times associated with more invasiveprocedures such as hysterectomy, myomectomy or UAE."

Dudi Machluf, Chief Executive Officer (Co-CEO) of Elbit Imaging, said:"InSightec's technology is the first non-invasive treatment for uterinefibroids approved for use by Japan's Ministry of Health, Labor and Welfare(MHLW), an accomplishment which speaks for itself. In receiving thisapproval, InSightec made significant progress towards increasing its activityin Japan and receiving reimbursement. We expect that InSightec will leveragethe great potential capitalized in this in this market."

About InSightec

InSightec Ltd. is a privately held company owned by Elbit Imaging,General Electric, MediTech Advisors, LLC and employees. It was founded in1999 to develop the breakthrough MR guided Focused Ultrasound technology andtransform it into the next generation operating room. Headquartered nearHaifa, Israel, the company has over 160 employees and has invested more than$130 million in research, development, and clinical investigations. Its U.S.headquarters are located in Dallas, Texas. For more information, please goto: http://www.insightec.com/

About Elbit Imaging Ltd.

The Activities of Elbit Imaging Ltd. are divided into the followingprincipal fields: (i) Shopping and Entertainment Centers - Initiation,construction, operation, management and sale of shopping and entertainmentcenters and other mixed-use real property projects, predominantly in theretail sector, located in Central and Eastern Europe and in India; (ii)Hotels - Hotel ownership, operation, management and sale, primarily in majorEuropean cities; (iii) Image Guided Treatment - Investments in the researchand development, production and marketing of magnetic resonance imagingguided focused ultrasound treatment equipment; (vi) Residential Projects -Initiation, construction and sale of residential projects and other mixed-usereal projects, predominantly residential, located in Eastern Europe and inIndia; and (v) Other Activities - (a) The distribution and marketing offashion apparel and accessories in Israel; (b) venture capital investments;and (c) investments in hospitals, and farm and dairy plants in India, whichare in preliminary stages.

Any forward-looking statements in our releases include statementsregarding the intent, belief or current expectations of Elbit Imaging Ltd.and our management about our business, financial condition, results ofoperations, and its relationship with its employees and the condition of ourproperties. Words such as "believe," "expect," "intend," "estimate" andsimilar expressions are intended to identify forward-looking statements butare not the exclusive means of identifying such statements. Actual resultsmay differ materially from those projected, expressed or implied in theforward-looking statements as a result of various factors including, withoutlimitation, the factors set forth in our filings with the Securities andExchange Commission including, without limitation, Item 3.D of our annualreport on Form 20-F for the fiscal year ended December 31, 2008, under thecaption "Risk Factors." Any forward-looking statements contained in ourreleases speak only as of the date of such release, and we caution existingand prospective investors not to place undue reliance on such statements.Such forward-looking statements do not purport to be predictions of futureevents or circumstances, and therefore, there can be no assurance that anyforward-looking statement contained our releases will prove to be accurate.We undertake no obligation to update or revise any forward-lookingstatements. All subsequent written or oral forward-looking statementsattributable to us or persons acting on our behalf are expressly qualified intheir entirety by the cautionary statements set forth in our filings with theSecurities and Exchange Commission including, without limitation, Item 3.D ofour annual report on Form 20-F for the fiscal year ended December 31, 2008,under the caption "Risk Factors."For Further Information: Company Contact: Investor Contact: Dudi Machluf Mor Dagan Chief Executive Officer (Co-CEO) Investor Relations Tel:+972-3-6086024 Tel:+972-3-516-7620 dudim@elbitimaging.com mor@km-ir.co.il

SOURCE Elbit Imaging Ltd.
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
QualiSystems TestShell now Maximizes Test Lab Reso...
S
AMP Receives Grant From the Bill & Melinda Gates F...